🏛️ Verified NIH Record • Updated 2026-08-05
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (NCT04099251)
A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy With Nivolumab Versus Placebo After Complete Resection of Stage IIB/C Melanoma
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 0088 — Birmingham, Alabama
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (130 Sites)
Showing the first 25 of 130 sites.
- Local Institution - 0088 — Birmingham, Alabama
- Local Institution - 0126 — Tucson, Arizona
- Local Institution - 0087 — Springdale, Arkansas
- Local Institution - 0080 — Los Angeles, California
- Local Institution - 0077 — San Francisco, California
- Local Institution - 0119 — San Francisco, California
- Local Institution - 0122 — San Jose, California
- Local Institution - 0121 — Vallejo, California
- Local Institution - 0109 — Vallejo, California
- Local Institution - 0120 — Vallejo, California
- Local Institution - 0091 — Aurora, Colorado
- Local Institution - 0089 — Washington D.C., District of Columbia
- Local Institution - 0141 — Atlanta, Georgia
- Local Institution - 0132 — Chicago, Illinois
- Local Institution - 0135 — Baltimore, Maryland
- Local Institution - 0078 — Boston, Massachusetts
- Local Institution - 0127 — Boston, Massachusetts
- Local Institution - 0143 — Boston, Massachusetts
- Local Institution - 0151 — Minneapolis, Minnesota
- Local Institution - 0081 — Robbinsdale, Minnesota
- Local Institution - 0079 — Omaha, Nebraska
- Local Institution - 0093 — Hackensack, New Jersey
- Local Institution - 0094 — New York, New York
- Local Institution - 0086 — Charlotte, North Carolina
- Local Institution - 0099 — Cleveland, Ohio
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.